'5 trials' diaporamas de présentation

Colin Baigent University of Oxford, UK SHARP Chief Investigator

US FDA Endocrinologic and Metabolic Drugs Advisory Committee, 2 November 2011. Study of Heart and Renal Protection (SHARP): Safety and efficacy of ezetimibe/simvastatin in patients with Chronic Kidney Disease (CKD). Colin Baigent University of Oxford, UK SHARP Chief Investigator.

1.29k views • 111 slides

Colin Baigent University of Oxford, UK SHARP Chief Investigator

US FDA Endocrinologic and Metabolic Drugs Advisory Committee, 2 November 2011. Study of Heart and Renal Protection (SHARP): Safety and efficacy of ezetimibe/simvastatin in patients with Chronic Kidney Disease (CKD). Colin Baigent University of Oxford, UK SHARP Chief Investigator.

1.11k views • 111 slides

Colin Baigent University of Oxford, UK SHARP Chief Investigator

US FDA Endocrinologic and Metabolic Drugs Advisory Committee, 2 November 2011. Study of Heart and Renal Protection (SHARP): Safety and efficacy of ezetimibe/simvastatin in patients with Chronic Kidney Disease (CKD). Colin Baigent University of Oxford, UK SHARP Chief Investigator.

1.11k views • 111 slides

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine. Rory Collins and Jane Armitage on behalf of the SEARCH Collaborative Group.

421 views • 31 slides

????????????

????????????. ?????? ?????? ?????, ????? ?????? ?????, ???? ???? ??"? ??????? ?????? ?"? ??????, ???????. ???? 1. ?? 45 ??? ???? ???? 30 ??? ??????, ???? ?? ??, BMI 28 ????? ?????? ?? ???? ?? ??????? ?? ??? ???? 69 ?????? : ????? ???? ????? 3 ???? ???? ????? ?? 25 ???

496 views • 31 slides

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine. Rory Collins and Jane Armitage on behalf of the SEARCH Collaborative Group.

378 views • 29 slides

Dustin C. Lee, Ph.D. Behavioral Pharmacology Research Unit

Cannabis Use Measures and Outcomes Assessed in Randomized Controlled Trials for Cannabis Use Disorder. Dustin C. Lee, Ph.D. Behavioral Pharmacology Research Unit Johns Hopkins University School of Medicine. Introduction. Cannabis use disorder (CUD) is prevalent

267 views • 26 slides

298 views • 8 slides

Mean ejection fraction effect size by number of discrepancies in reports

Mean ejection fraction effect size by number of discrepancies in reports. 10 8 6 4 2 0 -2. EF effect size ( + SE). 0 5 trials. 1-10 24 trials. 11-20 12 trials. 21-30 3 trials. > 30 5 trials. Number of discrepancies per trial. Nowbar et al., BMJ 2014.

72 views • 1 slides

Meta-Analysis ICU Intensive Insulin

118 views • 1 slides